Aptevo Therapeutics Inc. Files S-1 Registration Statement

TL;DR

<b>Aptevo Therapeutics Inc. has filed an S-1 registration statement for a public offering of securities.</b>

AI Summary

Aptevo Therapeutics Inc. (APVO) filed a IPO Registration (S-1) with the SEC on March 20, 2024. Aptevo Therapeutics Inc. filed an S-1 registration statement with the SEC on March 20, 2024. The filing is for a proposed sale of securities to the public, with the exact date to be determined. The company is incorporated in Delaware and its principal executive offices are located in Seattle, Washington. Marvin L. White is listed as President and Chief Executive Officer. The filing is categorized under SIC code 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking Aptevo Therapeutics Inc., this filing contains several important signals. This S-1 filing indicates Aptevo Therapeutics is preparing to raise capital through a public offering, which could fund its drug development pipeline. The registration statement provides a comprehensive overview of the company's business, financial condition, and risks, offering insight into its strategic direction and potential for growth.

Risk Assessment

Risk Level: medium — Aptevo Therapeutics Inc. shows moderate risk based on this filing. The company is in the pharmaceutical preparations industry and is filing an S-1, which is a registration statement for a public offering. This suggests potential future dilution and market volatility associated with such offerings, but the specific details of the offering and the company's financial health are not yet fully disclosed in this initial filing.

Analyst Insight

Monitor future filings for details on the offering size, pricing, and use of proceeds to assess the impact on existing shareholders and the company's growth prospects.

Key Numbers

• 2024-03-20 — Filing Date (Date of S-1 filing)
• 333-278103 — SEC File Number (Registration Number)
• 2834 — SIC Code (Pharmaceutical Preparations)
• 811567056 — IRS Number (Employer Identification Number)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• Marvin L. White (person) — President and Chief Executive Officer
• Sean M. Donahue (person) — Copies to
• Paul Hastings LLP (company) — Legal Counsel
• SoYoung Kwon (person) — Senior Vice President and General Counsel
• Charles E. Phillips (person) — Copies to
• Ellenoff Grossman & Schole LLP (company) — Legal Counsel
• 206-838-0500 (dollar_amount) — Business Phone

FAQ

Industry Context

Aptevo Therapeutics operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Regulatory Implications

The S-1 filing is a standard regulatory requirement for companies intending to offer securities to the public under the Securities Act of 1933.

What Investors Should Do

1. Review the full S-1 filing for detailed financial statements and risk factors.
2. Track subsequent SEC filings for updates on the public offering timeline and terms.
3. Analyze the company's pipeline and competitive landscape within the pharmaceutical sector.

Key Dates

• 2024-03-20: S-1 Filing — Registration statement filed with the SEC for a public offering.

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing to compare against for 'vs last filing' data.

Key Financial Figures

• $0.001 — #x201d;) of our common stock, par value $0.001 per share (common stock) together with
• $5.42 — sumed combined public offering price of $5.42 per share and common warrant (the last
• $0.0001 — of common stock at an exercise price of $0.0001 per share. Each pre-funded warrant is b
• $100,000 — cement agent fee, will be approximately $100,000. The delivery of the shares of common

Filing Documents

• apvo-2024-s1_-_public.htm (S-1) — 857KB
• apvo-ex4_19.htm (EX-4.19) — 156KB
• apvo-ex4_20.htm (EX-4.20) — 156KB
• apvo-ex4_21.htm (EX-4.21) — 311KB
• apvo-ex4_22.htm (EX-4.22) — 155KB
• apvo-ex5_1.htm (EX-5.1) — 31KB
• apvo-ex23_1.htm (EX-23.1) — 4KB
• apvo-exfiling_fees.htm (EX-FILING FEES) — 101KB
• img57496738_0.jpg (GRAPHIC) — 8KB
• img136687220_0.jpg (GRAPHIC) — 7KB
• img136687220_1.jpg (GRAPHIC) — 58KB
• img136687220_2.jpg (GRAPHIC) — 516KB
• img136687220_3.jpg (GRAPHIC) — 4KB
• 0000950170-24-034178.txt (&nbsp;) — 2588KB

USE OF PROCEEDS

USE OF PROCEEDS 10 CAPITALIZATION 11

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 14

description of securities we are offering

description of securities we are offering 19 PLAN OF DISTRIBUTION 23 I ncorporation of certain information by reference 26 WHERE YOU CAN FIND MORE INFORMATION 26 LEGAL MATTERS 27 EXPERTS 27 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under &#x201c; Where You Can Find More Information.&#x201d; You should carefully read this prospectus as well as additional information described under &#x201c; Incorporation of Certain Information by Reference ,&#x201d; before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have bee

View Full Filing

View this S-1 filing on SEC EDGAR